//
NOV
28
2018

AMP 2018 Workshop

How does the NeuMoDx 288 Molecular System handle quantitative EBV and BKV LDT implementation? Dr. Steve Young, Ph.D. of TriCore Reference Laboratories presented a full evaluation at this year’s #AMP2018. Fill out our form to download the slideshow presentation.
COMMENT Off
NOV
13
2018

Steven Young of TriCore Labs speaks about NeuMoDx at AMP 2018

NeuMoDx platforms are built to handle large volumes of sample in an automated fashion, integrating the entire molecular diagnostic process from sample to result. See what Dr. Steven Young has to say about these revolutionary molecular diagnostic systems.
COMMENT Off
OCT
31
2018

NeuMoDx™ Molecular announces today, the U.S. launch of its FDA 510(k) cleared NeuMoDx™ 288 Molecular System and its FDA Listed NeuMoDx™ 96 Molecular System at AMP Show in Texas

Ann Arbor, MI (November 1, 2018) – NeuMoDxTM Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today the US launch of its FDA 510(k) cleared NeuMoDxTM 288 Molecular System and its FDA Listed NeuMoDxTM  96 Molecular
COMMENT Off
SEP
17
2018

QIAGEN and NeuMoDx announce strategic partnership to offer next-generation systems for fully integrated molecular diagnostic testing

QIAGEN to launch two Sample to Insight systems in Europe and other markets, NeuMoDx to commercialize in the U.S. / Initial assay menu for infectious diseases and LDTs Hilden, Germany, and Ann Arbor, Michigan (September 17, 2018) – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime
COMMENT Off
JUL
01
2018

NeuMoDx Molecular Announces FDA 510(k) Clearance for its 288 Molecular System and GBS Assay

  Ann Arbor, Michigan (July 2018) – NeuMoDx Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today it has received FDA 510(k) clearance for its NeuMoDxTM 288 Molecular System and its NeuMoDxTM GBS Assay. The fully
COMMENT Off
JUL
01
2018

NeuMoDx to Present the NeuMoDx 288 Molecular System at the 70th Annual AACC in Chicago

  Ann Arbor, Michigan (July 1, 2018) – NeuMoDxTM Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today it will be previewing its FDA 510(k) cleared NeuMoDxTM 288 Molecular System during the 70th AACC Annual
COMMENT Off